Study wrapper · #941
Medical Management of Obesity: A Comprehensive Review of FDA-Approved and Investigational Therapies.
Raza SS, Zakir Z, Hashmat A, et al. Cureus. 2025.
DOI: 10.7759/cureus.96739PubMed: 41393574
Editor's note
This review surveys the obesity pharmacotherapy landscape, covering approved agents alongside investigational ones such as retatrutide. It summarizes efficacy, safety concerns, and patient-selection considerations without presenting new data. A reasonable orientation piece for readers new to the class.
Plain-language abstract
A narrative review of approved and investigational obesity medications, describing how semaglutide and tirzepatide have reshaped expectations and how retatrutide shows greater efficacy in early studies.
Related coverage
Weak / none
A qualitative study exploring experiences about using semaglutide for weight loss in a rural setting in Denmark - 'she is probably on the meds'.
Scandinavian journal of primary health caren=——2026
Mixed
GLP-1 receptor agonists in stroke prevention: a narrative review on emerging therapeutic frontiers.
Annals of medicinen=——2026
Weak / none
Cost-effectiveness of tirzepatide versus semaglutide for patients with obesity or overweight in the US: evidence from the SURMOUNT-5 head-to-head phase-3 trial.
Journal of medical economicsn=——2026